Skip to main content

UM SOM Vaccine Expert Warns of Risks of Influenza to Older Populations

September 28, 2017 | Joanne Morrison

Kathleen Neuzil, MD, MPH, FIDSA

CVD Director Kathleen Neuzil Says People 65 and Older Risk Severe Complications from Influenza

“Protect yourself and others by getting the flu shot” was the message from Kathleen Neuzil, MD, MPH, FIDSA, Director of the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM). Dr. Neuzil was among the speakers at a press conference hosted by the National Foundation for Infectious Diseases. U.S. Secretary of Health and Human Services, Thomas E Price, MD, also spoke at the press conference and urged people to get their flu shot. The panel members all received their flu shots following the press conference.

Dr. Neuzil cautioned that individuals 65 and older are at the highest risk of severe complications and even death. “As you age, your frailty increases and you are more likely to have severe consequences of influenza,” Dr. Neuzil said, noting that roughly 85% of flu-related deaths in the U.S. fall in this age group. Neuzil also explained that there are vaccines with stronger doses designed to accommodate aging immune systems. In addition to protecting our elderly population, the flu shot is an effective tool in stopping the spread of influenza to other vulnerable populations such as the very young or those with underlying heart conditions.

Officials at the press conference, including Dr. Price, all agreed that flu seasons are difficult to predict and can range from mild to severe. Flu seasons are “predictably unpredictable,” Dr. Neuzil said, noting that it takes roughly two weeks after vaccination for the flu shot to begin working, so it’s best to get the flu shot as soon as possible.

According to recent data from the Centers for Disease Control and Prevention, influenza vaccination coverage for all ages across the U.S. was 46.8 percent during last year’s flu season. That means more than half of the U.S. population was unprotected from influenza. While coverage in older adults is better at 65.3% , it’s not good enough, according to Dr. Neuzil.

“It is critical to maintain the highest level of vaccination coverage for older adults because they are disproportionately affected by flu. Vaccination not only reduces the chance that older adults will get the flu, it can also help keep them out of the hospital by reducing the severity of the infection and related complications if they do get the flu,” said Dr. Neuzil.

About the University of Maryland School of Medicine

Commemorating its 210th Anniversary, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academies of Science, Engineering and Medicine, and a distinguished recipient of the Albert E. Lasker Award in Medical Research. With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically-based care for more than 1.2 million patients each year. The School has over 2,500 students, residents, and fellows, and nearly $450 million in extramural funding, with more than half of its academic departments ranked in the top 20 among all public medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System (“University of Maryland Medicine”) has a total budget of $5 billion and an economic impact of nearly $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th-highest public medical school in research productivity, is an innovator in translational medicine with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu/.

About the Center for Vaccine Development

Since its inception in 1974, the CVD has worked to eliminate vaccine-preventable diseases. The CVD has created and tested vaccines against cholera, typhoid fever, paratyphoid fever, non-typhoidal salmonella disease, shigellosis (bacillary dysentery), Escherichia coli diarrhea, nosocomial pathogens, tularemia, influenza, and other infectious diseases. Learn more about the CVD.

Learn More

• Center for Vaccine Development (CVD)

•  National Foundation for Infectious Diseases

Contact

Department of Anesthesiology
(410) 328-6120 (phone)
(410) 328-5531 (fax)
newsletter@som.umaryland.edu

University of Maryland School of Medicine
Joanne Morrison
Director of Marketing and Public Relations
University of Maryland School of Medicine
jmorrison@som.umaryland.edu
Office:(410) 706-2884
Mobile:(202) 841-3369

Related stories

    Wednesday, April 05, 2023

    UM School of Medicine Researchers Chart Path Forward on Developing mRNA Vaccines for Infections Beyond COVID-19

    After helping to develop and test new mRNA technologies for COVID-19 vaccines, University of Maryland School of Medicine (UMSOM) researchers and scientists are turning their attention to utilizing this innovative technology to ward off other infectious diseases like malaria and influenza. Last month, UMSOM faculty in the Center for Vaccine Development and Global Health (CVD) launched a new clinical trial to investigate the use of mRNA technologies to create a vaccine against malaria. CVD Director Kathleen M. Neuzil, MD, MPH, FIDSA also provided commentary in the nation’s leading medical journal on the feasibility of using mRNA to develop a universal influenza vaccine that could eliminate the need for seasonal shots.


    Thursday, July 02, 2020

    UMSOM Researchers Help Weigh Role of Human Challenge Studies for COVID-19 Vaccine Development

    Members of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Group, which includes Kathleen Neuzil, MD, MPH, DTPH, the Myron M. Levine, MD, DTPH Professor in Vaccinology and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), assessed the practical considerations and prerequisites for using controlled human infection models (CHIMs) to support development of a SARS-CoV-2 Vaccine.


    Monday, October 21, 2019

    UM School of Medicine's Kathleen M Neuzil Elected as Member of Prestigious National Academy of Medicine

    Kathleen M. Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), has been elected as a member of the National Academy of Medicine (NAM), in recognition of her pivotal research that has informed and shaped global vaccine and public health policy. Her membership was announced at the annual NAM meeting in Washington, D.C., placing her among the 2,178 U.S. members of this important organization. Membership in the Academy is considered one of the highest honors for individuals who have made major contributions to the advancement of the medical sciences, health care and public health.


    Friday, September 20, 2019

    UM School of Medicine's Center for Vaccine Development and Global Health Receives NIH Contract of up to More than $200 Million for Influenza Research

    Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) and Dean E. Albert Reece, MD, PhD, MBA, announced that CVD has been awarded a contract from the National Institute of Allergy and Infectious Diseases (NIAID), with total funding up to more than $200 million over seven years if all contract options are exercised.


    Friday, March 08, 2019

    UMSOM Researchers Unveil Progress and Challenges in Introducing Typhoid Conjugate Vaccine in Sub-Saharan Africa and Asia

    Each year there are nearly 11 million cases of typhoid, a disease that is spread through contaminated food, drink and water. Researchers at the University of Maryland School of Medicine are leading an international consortium that is studying the impact of a typhoid conjugate vaccine (TCV) in an effort to accelerate introduction of the vaccine in countries in sub-Saharan Africa and Asia where there is a high burden of typhoid.


    Monday, December 03, 2018

    UMSOM and Groupe De Recherche Action En Sante Begin Second Typhoid Conjugate Vaccine Study in Africa

    A new study has been launched in Burkina Faso for Bharat Biotech’s typhoid conjugate vaccine (TCV). It is the second clinical study underway in Africa for the vaccine and the first in West Africa. The vaccine study is a joint effort by the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine, (UMSOM) and Groupe de Recherche Action en Santé (GRAS) in Burkina Faso.


    Friday, November 02, 2018

    UMSOM Global Health Expert Named to Prestigious World Health Organization Immunization Panel

    Kathleen Neuzil, MD, MPH, Professor of Medicine and Pediatrics and Director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM), has been named to the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization.


    Monday, April 23, 2018

    UM School of Medicine Launches Newly Organized Center for Vaccine Development and Global Health Under Leadership of International Vaccine Expert Dr. Kathleen Neuzil

    University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today the launch of a newly organized Center for Vaccine Development and Global Health (CVD). The new Center will be led by UMSOM Professor of Medicine and Pediatrics, Kathleen Neuzil, MD MPH, FIDSA, one of the world’s most influential research scientists and advocates in vaccine development and policy.


    Friday, August 18, 2017

    Tenth Annual Kids Mini-Med School Celebrates Graduation Day

    In 2008, the University of Maryland School of Medicine expanded its Mini-Med School program to Kids Mini-Med at the Salvation Army’s Franklin Square Boys & Girls Club in West Baltimore. Doctors from the School visited the camp weekly to teach about health and encourage the young campers (ages 5 to 13) to consider careers in science and medicine. The idea took off and over the past decade, our faculty have touched the lives of several hundred campers.


    Tuesday, August 01, 2017

    Preeminent UM SOM Scientist Elected to National Foundation for Infectious Diseases Board

    Kathleen M. Neuzil, MD, MPH, FIDSA, Professor of Medicine and Director of the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM), was elected to serve a three-year term to the Board of Directors for the National Foundation for Infectious Diseases (NFID).


    Monday, May 15, 2017

    U.S. CDC Recommends Use of Cholera Vaccine Developed by University of Maryland School of Medicine

    A cholera vaccine developed by scientists at the University of Maryland School of Medicine’s Center for Vaccine Development (CVD) has been recommended by the U.S. Centers for Disease Control and Prevention (CDC) for use as a protection for U.S. adults traveling to areas with cholera. The CDC’s latest recommendation was published on May 11, in Morbidity and Mortality Weekly Report.


    Thursday, November 10, 2016

    International Consortium Receives $36.9 Million Grant to Fight Typhoid

    Typhoid fever, a bacterial infection that causes high fever and other disabling symptoms, remains a serious global problem in the developing world: it kills almost a quarter of a million people annually, and infects about 21 million.


    Thursday, September 22, 2016

    University of Maryland School of Medicine Holds Inaugural Global Health Summit

    The Institute for Global Health (IGH) at the University of Maryland School of Medicine (UM SOM) will hold its first Global Health Summit on September 26. The event, which will take place from noon to 6 p.m. in the SMC Campus Center at 621 W. Lombard Street, will seek to foster collaboration among scientists and promote new and innovative global health research at UM SOM, as well as at other schools at the University of Maryland, Baltimore (UMB). Faculty and staff from UM SOM, as well as other schools are welcome at the event.


    Thursday, August 04, 2016

    UM SOM is Center Stage in Testing National Institutes of Health Zika Vaccine

    UM SOM'S Center for Vaccine Development, tapped previously for Ebola vaccine, now steps up to help develop first Zika vaccine.


    Wednesday, June 29, 2016

    UM SOM Researchers Awarded Grant to Use Innovative Alternative to Autopsies to Better Understand Child Mortality

    Kathleen Neuzil, MD, MPH, director of the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM), and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that CVD has been awarded a large grant from the Bill & Melinda Gates Foundation for research that will help determine why so many children under five are dying in the world’s poorest countries. The grant will fund use of an innovative alternative to traditional autopsy known as minimally invasive tissue sampling. The technique, which involves the collection of tissue samples with fine needles, allows researchers to quickly identify the cause of death, and help illuminate ways to save lives and improve the health of children in these vulnerable areas.


    Tuesday, April 12, 2016

    UM SOM Researcher Dr. Kathleen Neuzil Honored by Vanderbilt University School of Medicine

    The Vanderbilt University School of Medicine (VUSM) has announced that Kathleen Neuzil, MD, MPH, director of the Center for Vaccine Development at the University of Maryland School of Medicine (UM SOM), has received the 2016 Vanderbilt University School of Medicine Distinguished Alumni Award.